Fresenius Medical extends HighVolumeHDF dialysis in Mexico

Fresenius Medical (FMS) will extend High-Volume Hemodiafiltration access for patients in seven out of 10 centers in Mexico, by partnering with the country’s Coordination of National Institutes of Health and Specialty Hospitals to develop a pilot program that provides low-income patients without medical coverage in Mexico with access to hemodialysis therapies. Fresenius Medical Care Mexico and CCINSHAE signed a two-year contract to enable the installation of the Fresenius Medical Care 5008S CorDiax technology in participating renal treatment centers in CCINCSHAE Centers in Mexico City and its metropolitan area, for a total of 150 systems in all. In the future, the company wants to bring HighVolumeHDF therapy – already widely used in Europe, Latin America, and Asia Pacific – for people living with kidney diseases in the U.S. In May 2025, the company received FDA 510(k) clearance for the updated version of its new, hemodiafiltration-capable 5008X CAREsystem with additional features, a benchmark enabling the next steps in the company’s broader commercialization efforts across the U.S. later this year, followed by a full-scale commercial launch in 2026.